Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer

Published: Friday, Apr 19, 2019
With the introduction of agents such as bevacizumab and PARP inhibitors, the treatment spectrum for ovarian cancer has evolved from a broad utilization of cytotoxic agents into more tailored approaches.1 Additional molecular targets are being investigated in an effort to improve the clinical outcomes of recurrent ovarian cancer. One such target is folate receptor α (FRα), which modulates folate uptake, thereby facilitating the activation of tumor growth signals and DNA synthesis.2,3 FRα expression may also enhance tumor cells’ antiapoptotic ability, rendering them resistant to chemotherapy.3,4

Several FRα-targeting agents that are in active development represent different drug classes and mechanisms of action. This article reviews investigational data associated with these agents, with an emphasis on the recent development and therapeutic potential of antibody–drug conjugates (ADCs) for the treatment of ovarian cancer.

Early FRα-Targeting Agents

Farletuzumab

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x